Abstract:Abstract To date, dysregulation of more than 450 RNA-binding proteins (RBPs) across a multitude of cancers has been implicated in tumorigenesis and chemoresistance. In fact, emerging evidence suggests RBPs are principal modulators of every hallmark of cancer progression. Functionally, RBPs are believed to modulate the stability, localization, and translation of transcripts encoding for virtually all known oncogenes and tumor suppressor genes. Consequently, aberrant expression of RBPs may contribute to the malignant transformation of cancer cells through enhancing the expression of oncogenes or decreasing the expression of tumors suppressor genes, such as TP53. As a potent transcription factor, TP53 is a leading regulator of numerous signaling pathways involved in tumor suppression. While mutation or deletion of TP53 contributes to tumorigenesis in more than half of all human cancers, suppression of wild-type TP53 expression also drives tumorigenesis. Thus far, multiple RBPs have been implicated in the repression of wild-type TP53, such as RNA-binding motif protein 38 (RBM38). Specifically, RBM38 interacts with eukaryotic translation initiation factor 4E (EIF4E) on the TP53 transcript, preventing EIF4E from binding to TP53 m7G cap, thus inhibiting TP53 translation. We previously demonstrated that Pep8, an 8 amino acid peptide derived from RBM38, disrupts the RBM38-EIF4E complex enhancing TP53 expression. Moreover, Pep8 alone or in combination with doxorubicin, significantly decreased tumor xenograft growth. As activation of wild-type TP53 by targeting non-genetic mechanisms that inhibit TP53 expression is a promising therapeutic tactic for malignancies that carry wild-type TP53, we are developing more efficacious Pep8 derivatives as a novel therapeutic approach for cancers that express wild-type TP53. Citation Format: Chris August Lucchesi, Jin Zhang, Xinbin Chen. Targeting the RBM38-EIF4E complex to increase wild-type p53 as a novel cancer therapeutic strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1037.

Inhibition of Ribosome Biogenesis in vivo Causes p53-Dependent Death and p53-Independent Dysfunction

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Ribosomal Protein S27-like is a Physiological Regulator of P53 That Suppresses Genomic Instability and Tumorigenesis

The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells

Ribosomal protein RPL11 haploinsufficiency causes anemia in mice via activation of the RP-MDM2-p53 pathway

Mice Deficient in the RNA-Binding Protein Zfp871 Are Prone to Early Death and Steatohepatitis in Part through the p53-Mdm2 Axis

Ribosomal Protein S27L is a Direct P53 Target That Regulates Apoptosis.

Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress

A Glycopeptidyl-Glutamate Epimerase for Bacterial Peptidoglycan Biosynthesis.

Possible technique to measure ventricular volume using electrical impedance measurements with an oesophageal electrode

Less invasive coronary surgery: consensus from the Oxford meeting.

53BP1 Loss Rescues Embryonic Lethality but Not Genomic Instability of BRCA1 Total Knockout Mice

Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2–MRN–ATM axes

p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways

Chromosome Stability, in the Absence of Apoptosis, is Critical for Suppression of Tumorigenesis in Trp53 Mutant Mice

RPL23 Links Oncogenic RAS Signaling to P53-Mediated Tumor Suppression

p53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice